Theriva Biologics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-4.8M | $6.2M |
| FY2021 | — | $65.4M | $67.3M |
| FY2022 | $221.0K | $68.0M | $52.3M |
| FY2023 | $162.0K | $37.0M | $23.2M |
| FY2024 | $92.0K | $19.1M | $11.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-4.8M | $6.2M |
| FY2021 | — | $65.4M | $67.3M |
| FY2022 | $221.0K | $68.0M | $52.3M |
| FY2023 | $162.0K | $37.0M | $23.2M |
| FY2024 | $92.0K | $19.1M | $11.6M |